Status:
COMPLETED
Clinical Trial Ceftriaxone in Subjects With ALS
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Amyotrophic Lateral Sclerosis
ALS
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
Detailed Description
It is known that nerve cells called motor neurons die in the brains and spinal cords of people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is unknown. Researchers t...
Eligibility Criteria
Inclusion
- Participants will be people with ALS, at least 18 years of age.
- Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration.
- Participants should live within a reasonable distance of the study site, due to frequent study visits.
Exclusion
- Participants cannot be taking any other experimental medications for ALS, or have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz).
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
513 Patients enrolled
Trial Details
Trial ID
NCT00349622
Start Date
July 1 2006
End Date
November 1 2012
Last Update
April 21 2014
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
2
University of California, Davis
Davis, California, United States, 95819
3
University of California, San Francisco- Fresno
Fresno, California, United States, 93701
4
Loma Linda University School of Medicine (CA)
Loma Linda, California, United States, 92354